These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas. Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193 [TBL] [Abstract][Full Text] [Related]
4. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590 [TBL] [Abstract][Full Text] [Related]
5. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111 [TBL] [Abstract][Full Text] [Related]
6. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
7. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467 [TBL] [Abstract][Full Text] [Related]
8. Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging. Cluceru J; Interian Y; Phillips JJ; Molinaro AM; Luks TL; Alcaide-Leon P; Olson MP; Nair D; LaFontaine M; Shai A; Chunduru P; Pedoia V; Villanueva-Meyer JE; Chang SM; Lupo JM Neuro Oncol; 2022 Apr; 24(4):639-652. PubMed ID: 34653254 [TBL] [Abstract][Full Text] [Related]
9. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286 [TBL] [Abstract][Full Text] [Related]
10. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
11. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747 [TBL] [Abstract][Full Text] [Related]
12. Streamlined Intraoperative Brain Tumor Classification and Molecular Subtyping in Stereotactic Biopsies Using Stimulated Raman Histology and Deep Learning. Reinecke D; Ruess D; Meissner AK; Fürtjes G; von Spreckelsen N; Ion-Margineanu A; Khalid F; Blau T; Stehle T; Al-Shugri A; Büttner R; Goldbrunner R; Ruge MI; Neuschmelting V Clin Cancer Res; 2024 Sep; 30(17):3824-3836. PubMed ID: 38976016 [TBL] [Abstract][Full Text] [Related]
13. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
14. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient. Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266 [TBL] [Abstract][Full Text] [Related]
15. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
16. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas. Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259 [TBL] [Abstract][Full Text] [Related]
17. Diffuse glioma, not otherwise specified: imaging-based risk stratification achieves histomolecular-level prognostication. Jang EB; Kim HS; Park JE; Park SY; Nam YK; Nam SJ; Kim YH; Kim JH Eur Radiol; 2022 Nov; 32(11):7780-7788. PubMed ID: 35587830 [TBL] [Abstract][Full Text] [Related]
18. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
19. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. Sonoda Y Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379 [TBL] [Abstract][Full Text] [Related]
20. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]